Dr. Shore on the TERRAIN Trial for Prostate Cancer
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses the results of the TERRAIN trial.
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses the results of the TERRAIN trial.
The TERRAIN trial was a prospective, double-blind study randomizing patients to enzalutamide or bicalutamide. Patients were included who had asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC), Shore explains.
A 10-month radiographic progression-free survival benefit was seen in patients treated with enzalutamide versus bicalutamide. Patients in the enzalutamide arm also saw a decline in prostate-specific antigen levels.
The phase II study, which enrolled 375 patients, demonstrated the advantages of treatment with enzalutamide compared with bicalutamide, Shore says.
<<<
